Legal Bilingual Account Manager

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process

London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence

Data from studies conducted in more than 200 countries supports greater access to research and facilitates systematic reviews, clinical trial design, medical device approvals and improved drug safetyLONDON, May 6, 2025 /PRNewswire/ -- Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device.Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and R&D organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence. This process becomes challenging when data must be sourced from differing platforms, and regulatory and compliance requirements continue to evolve.The addition of ClinicalTrials.gov data to Embase will improve researcher workflows by making clinical data searchable within Embase's user-friendly interface